Investors & Media

press releases

Date Title Teaser
06/15/18
Summary Togglebluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association

– 7/8 non-β 0 /β 0 patients with ≥ 6 months follow-up producing normal or near-normal amounts of total hemoglobin (11.1 – 13.3 g/dL) and are transfusion free in Northstar-2 Study – – 8/10 of non-β 0 /β 0 patients achieving and maintaining transfusion independence for up to 3 years in Northstar

06/15/18
Summary Togglebluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association

– All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbA T87Q – – First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbA T87Q at 6 months – – Company to hold conference call and webcast today, June 15 ,

06/05/18
Summary Togglebluebird bio Announces Investor Events in June

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in June: Jefferies Global Healthcare Conference , Thursday, June 7 , at 10:00 a.m.

06/01/18
Summary ToggleUpdated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting High rates of response that were both deep and durable were seen at the highest dose levels. Median PFS of approximately one year achieved in heavily pre-treated patients in the active doses of the dose escalation cohort Consistent response observed for both low and high BCMA expression levels
05/23/18
Summary ToggleFDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious

05/17/18
Summary Togglebluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association

- Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes – - Oral presentation of interim data from patients treated with updated study protocol of Phase 1 HGB-206 study of

05/16/18
Summary Togglebluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

– Presentation will include safety and efficacy data from 21 patients treated in dose-escalation phase and early data from patients treated in dose-expansion phase – – Additional poster exploring the significance of MRD negativity in patients in this study to be presented – – Company to host

05/08/18
Summary Togglebluebird bio to Present at Investor Conferences in May

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Deutsche Bank’s 43 rd Annual Health Care Conference , Wednesday, May 9 , at 10:00 a.m.

05/02/18
Summary Togglebluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress

– Completed Northstar study of LentiGlobin in transfusion dependent β-thalassemia (TDT) – – Entered into co-development and co-promotion agreement for bb2121 with Celgene – – Ended quarter with $1.57 billion in cash, cash equivalents and marketable securities – CAMBRIDGE, Mass.

04/18/18
Summary Togglebluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

– Majority (12/13) of patients with non-β 0 /β 0 genotypes were transfusion-free at median 27 months following LentiGlobin treatment – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced interim data published in the New England Journal of Medicine

04/16/18
Summary Togglebluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2018-- bluebird bio, Inc. (Nasdaq:BLUE) today announced that members of the management team will present at Alliance for Regenerative Medicine’s 6 th Annual Cell & Gene Therapy Investor Day on Tuesday, April 17 , at 11:25 a.m.

03/28/18
Summary Togglebluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

- bluebird and Celgene will share 50% of U.S. costs and profits - - bluebird to receive milestones and royalties on ex-U.S. sales - CAMBRIDGE, Mass. & SUMMIT, N.J. --(BUSINESS WIRE)--Mar. 28, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the

03/07/18
Summary Togglebluebird bio to Present at Investor Conferences in March CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 7, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
02/21/18
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress – Company expanding organization and capabilities to prepare three programs for regulatory filing in the next two years – – LentiGlobin in transfusion-dependent β-thalassemia (TDT) planned to be filed for marketing authorization in 2018 – – bb2121 in relapsed/refractory multiple myeloma planned to
02/14/18
Summary Togglebluebird bio Appoints Alison Finger as Chief Commercial Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed Alison Finger as chief
02/02/18
Summary Togglebluebird bio to Present at LEERINK Partners Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2018-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
01/08/18
Summary Togglebluebird bio Announces Closing of Over-Allotment Option in Public Offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has issued an additional
12/21/17
Summary Togglebluebird bio to Present at Investor Conferences in January CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 21, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
12/12/17
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 12, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of
12/11/17
Summary Togglebluebird bio Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 11, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public
12/11/17
Summary Togglebluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting – Two of three patients with severe sickle cell disease show >45 percent total anti-sickling hemoglobin levels and meaningful clinical improvement; all three show rising trajectory of HbA T87Q production in first six months post-drug product infusion – – Ongoing transfusion independence up to 3.8
12/10/17
Summary Togglebluebird bio Presents New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting
12/10/17
Summary Togglebluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
12/10/17
Summary ToggleCelgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
12/07/17
Summary Togglebluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop next-generation liquid and solid tumor product candidates – CAMBRIDGE, Mass.
11/29/17
Summary Togglebluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients – Company executing long-term strategy to develop broad manufacturing capabilities for both vector supply and drug product supply to support clinical development and commercialization across pipeline - - bluebird to receive Economic Development Award from NCBiotech upon meeting job creation targets
11/16/17
Summary ToggleCelgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma Designations based on preliminary clinical data from ongoing phase I study of bb2121 in heavily pre-treated multiple myeloma SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 16, 2017-- Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a
11/16/17
Summary Togglebluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype – Study to enroll approximately fifteen adult, adolescent and pediatric patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 16, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T
11/01/17
Summary Togglebluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting - 11 total abstracts accepted, including updated data from Northstar-2 (HGB-207) Phase 3 study of LentiGlobin in patients with TDT and non-β0/β0 genotypes, HGB-205 study of LentiGlobin in patients with SCD and TDT, and CRB-401 study of bb2121 anti-BCMA CAR T in patients with relapsed/refractory
11/01/17
Summary Togglebluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress - 11 presentations across severe genetic diseases, immunotherapy and gene editing programs to be presented at the American Society of Hematology (ASH) Annual Meeting – - Early data from patients treated under the amended study protocol in HGB-206 Phase 1 study in patients with severe sickle cell
10/31/17
Summary Togglebluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 31, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
10/06/17
Summary Togglebluebird bio to Present at Chardan Gene Therapy Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
10/04/17
Summary Togglebluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine – Additional follow-up data to be included in poster presentation at Child Neurology Society (CNS) Annual Meeting – – 15/17 (88%) of the patients infused with Lenti-D drug product remain alive and free of major functional disabilities (MFDs), the primary efficacy endpoint of the trial – – No
09/28/17
Summary Togglebluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma - Celgene has exercised its option to exclusively license bb21217 under its collaboration with bluebird bio – - bluebird bio to receive $15 million option exercise payment from Celgene - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2017-- bluebird bio, Inc.
09/20/17
Summary Togglebluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed Mary
09/13/17
Summary Togglebluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2017-- bluebird bio, Inc . (NASDAQ: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that the expansion cohort of
09/06/17
Summary Togglebluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting — Natural history and observational study data to be included in oral presentation at International Congress of Inborn Errors of Metabolism (ICIEM) — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially
09/01/17
Summary Togglebluebird bio to Present at Investor Conferences in September CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
08/09/17
Summary Togglebluebird bio to Present at Wedbush PacGrow Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
08/02/17
Summary Togglebluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress – Completed enrollment in Northstar -2, Phase 3 study of LentiGlobin TM drug product in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes – – Presented updated clinical results from studies in relapsed/refractory multiple myeloma, TDT and severe sickle cell disease
06/27/17
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of
06/26/17
Summary Togglebluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD) – 15/17 patients (88%) in initial study cohort remain free of major functional disabilities (MFDs) at 24 months – – Expansion cohort enrolling additional patients to gain European manufacturing experience – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2017-- bluebird bio, Inc.
06/23/17
Summary Togglebluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting - Drug product vector copy number (DP VCN) and percentage of lentiviral vector positive cells (LVV+) for initial 7 drug product lots manufactured in Northstar -2 (HGB-207) are consistently higher than in Northstar (HGB-204) with median DP VCN of 3.0 – - Initial results show that the three patients
06/23/17
Summary Togglebluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting –Ongoing transfusion independence up to 3.5 years in patients with transfusion-dependent β-thalassemia (TDT); three patients have discontinued iron chelation – –First patient with severe sickle cell disease (SCD) treated with gene therapy continues to show clinically meaningful improvement in
06/08/17
Summary Togglebluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed John O.
06/05/17
Summary Togglebluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting – 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 10 6 ) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% – – 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete
06/01/17
Summary Togglebluebird bio to Present at Two Investor Conferences in June CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
05/23/17
Summary Togglebluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy – Collaboration includes industry leaders; aims to develop strategies for sustainable, value-based approach to access transformative gene therapy treatments – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing
05/18/17
Summary Togglebluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting – Presentations include early data from Northstar -2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes and updated data from HGB-205 study in TDT and severe sickle cell disease (SCD) – – Encore presentation of data from CRB-401
05/17/17
Summary Togglebluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting –Presentation will include safety and efficacy data from 18 patients with up to 12 months of follow-up– –Company to host event with live webcast, Monday, June 5 , 6:30 p.m. CT– CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2017-- bluebird bio, Inc.
05/03/17
Summary Togglebluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress – Case study on first patient with severe sickle cell disease (SCD) treated with gene therapy published in New England Journal of Medicine – – Appointed Derek Adams, Ph.D. Chief Technology and Manufacturing Officer and Joanne Smith-Farrell , Ph.D.
05/02/17
Summary Togglebluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2017-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with GlaxoSmithKline Intellectual Property Development Limited (GSK).
05/02/17
Summary Togglebluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2017-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG . “bluebird bio is a pioneer in the field of lentiviral vector-based
04/26/17
Summary Togglebluebird bio to Present at Upcoming Investor Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
03/20/17
Summary Togglebluebird bio Appoints New Senior Manufacturing and Corporate Development Executives CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Derek Adams , Ph.D.
03/01/17
Summary Togglebluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine – Patient treated with LentiGlobin TM drug product demonstrates high levels (~50% of total hemoglobin) of anti-sickling hemoglobin (HbA T87Q ) 15 months after treatment – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to
02/28/17
Summary Togglebluebird bio to Present at Two Investor Conferences in March CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
02/22/17
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress – Presented interim phase 1 dose escalation data for anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma at EORTC-NCI-AACR Meeting – – Presented data from clinical studies of LentiGlobin TM drug product in patients with transfusion-dependent β-thalassemia (TDT)
02/03/17
Summary Togglebluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease - LentiGlobin TM drug product had a vector copy number (DP VCN) of 3.3 copies/diploid genome, with 83% of cells lentiviral vector sequence positive (LVV+) – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 3, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing
01/04/17
Summary Togglebluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced today that Nick Leschly , chief
12/15/16
Summary Togglebluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement CAMBRIDGE, Mass. & MUNICH--(BUSINESS WIRE)--Dec. 15, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer and apceth Biopharma GmbH (
12/14/16
Summary Togglebluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia – LentiGlobin drug product vector copy number (DP VCN) of 2.9 copies/diploid genome; 77% of cells lentiviral vector sequence positive (LVV+) – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 14, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially
12/06/16
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of
12/06/16
Summary Togglebluebird bio Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public
12/05/16
Summary Togglebluebird bio Provides Updates on HSC Gene Therapy Programs – LentiGlobin TM drug product manufactured with process 2 for two patients in HGB-206 and HGB-207 confirms two-to-threefold increase in vector copy numbers (VCNs) observed in retrospective in vitro analyses of patients’ transduced cells – – Company to host event at ASH with live webcast, Monday,
12/03/16
Summary Togglebluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - First patient with severe sickle cell disease treated with gene therapy remains free of clinical symptoms 21 months after receiving LentiGlobin Drug Product - - Ongoing transfusion independence and sustained production of HbA T87Q in patients with transfusion-dependent β-thalassemia - - Company
12/02/16
Summary Togglebluebird bio Announces Management Appointments - Susanna High named chief operating officer – - Andrew Obenshain named head of Europe – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 2, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and
11/30/16
Summary Togglebluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma – 100% of patients (n=6) in second and third dose cohorts achieved an objective response; two patients MRD-negative; overall response rate ( ORR ) is 78% – – Two patients achieved stringent complete responses, with 6 and 4 months follow-up – – Among all dosed patients (n=11), no dose-limiting
11/14/16
Summary Togglebluebird bio to Present New Data from Novel Anti-BCMA CAR T Cell Therapy bb2121 at EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim data from its study of
11/03/16
Summary Togglebluebird bio to Present New Data from Three LentiGlobinTM Clinical Studies at American Society of Hematology (ASH) Annual Meeting – Data from the Northstar (HGB-204) study of LentiGlobin drug product in transfusion-dependent β-thalassemia (TDT) show that all five patients with non-β 0 /β 0 genotypes and ≥12 months of follow-up remained free of transfusions, and patients with β 0 /β 0 genotypes and ≥12 months of follow-up
11/02/16
Summary Togglebluebird bio Reports Third Quarter 2016 Financial Results and Recent Operational Progress - Initiated HGB-207 Phase 3 study of LentiGlobin™ drug product in patients with transfusion-dependent beta-thalassemia (TDT) with non β 0 /β 0 genotypes – - HGB-207 and all studies of LentiGlobin to incorporate manufacturing process 2 going forward – - Provided update on manufacturing process 2,
11/01/16
Summary Togglebluebird bio to Present at Two Investor Conferences in November CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
10/13/16
Summary Togglebluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day – Consistently demonstrated improved vector copy number (VCN) in transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) patient cells in vitro with manufacturing Process 2 – –Implementing plan to optimize patient outcomes in severe SCD – –Achieved general agreement on
10/06/16
Summary Togglebluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the agenda and speakers for its
09/29/16
Summary Togglebluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene’s proprietary TCR technology platform and bluebird bio’s lentiviral vector, genome editing, synthetic biology, and manufacturing capabilities Medigene responsible for the generation and delivery of the
09/21/16
Summary ToggleLentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 21, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that the European Medicines
09/09/16
Summary Togglebluebird bio Announces Webcast of Gene Therapy Day CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 9, 2016-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it will hold an analyst
09/08/16
Summary Togglebluebird bio Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia -- HGB-207 trial to be conducted with enhancements to transduction process under the same IND as previous studies of LentiGlobin -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2016-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene
08/30/16
Summary Togglebluebird bio to Present at Four Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 30, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
08/04/16
Summary Togglebluebird bio to Present at Wedbush PacGrow Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
08/03/16
Summary Togglebluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress – Announced long-term commercial manufacturing agreement with Lonza – – Presented data on gene editing platform at American Society of Hematology (ASH) Workshop on Genome Editing – – Received Orphan Drug Designation for bb2121 in Multiple Myeloma – – Presented interim clinical data from Starbeam
07/18/16
Summary Togglebluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 18, 2016-- bluebird bio, Inc.  (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical
06/09/16
Summary ToggleLonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug Products Basel (CH) and Cambridge, MA (USA), 9 June 2016 – Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based
05/23/16
Summary Togglebluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
05/09/16
Summary Togglebluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2016-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced the presentation of
05/04/16
Summary Togglebluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress – Presented interim clinical data from Starbeam study of Lenti-D TM in cerebral adrenoleukodystrophy (CALD) at American Academy of Neurology (AAN) Annual Meeting – – Ten abstracts accepted for presentation at American Society for Gene and Cell Therapy (ASGCT) Meeting – – Advanced Company’s first
04/27/16
Summary Togglebluebird bio to Present at Two Upcoming Investor Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 27, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today announced that members of the management team will
04/20/16
Summary Togglebluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D™ at AAN 2016 Annual Meeting First clinical data to be presented from Phase 2/3 Starbeam Study; Company to host investor webcast and conference call today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially
04/18/16
Summary Togglebluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced that data from
03/03/16
Summary Togglebluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session at AAN 2016 Annual Meeting CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 3, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from the
03/02/16
Summary Togglebluebird bio to Present at Three Upcoming Investor Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 2, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today announced that members of the management team will
02/25/16
Summary Togglebluebird bio Announces Transition of Chief Financial Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2016-- bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Jim DeTore, chief financial
02/24/16
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Progress -- Treated first patient in CRB-401 study of anti-BCMA CAR T bb2121 in relapsed/refractory multiple myeloma -- -- Announced that Celgene has exercised its option to license bb2121 -- -- Presented LentiGlobin clinical data in transfusion-dependent ß-thalassemia and severe sickle cell disease at the
02/17/16
Summary Togglebluebird bio Announces First Patient Treated with bb2121 in CRB-401 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma Celgene has agreed to exercise its option to exclusively license bb2121 under global strategic collaboration bluebird bio to receive $10 million option exercise payment from Celgene CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 17, 2016-- bluebird bio, Inc.
01/05/16
Summary Togglebluebird bio to Present at the 34th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 5, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Nick Leschly , chief
12/06/15
Summary Togglebluebird bio Presents Pre-Clinical and Manufacturing Data from CAR T Oncology Programs at ASH Annual Meeting Company to webcast investor event, Sunday, December 6 at 8:30 p.m. ET ORLANDO, Fla. --(BUSINESS WIRE)--Dec. 6, 2015-- bluebird bio, Inc. (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based
12/06/15
Summary Togglebluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 and HGB-206 Studies of LentiGlobin® at ASH Annual Meeting Two patients with beta-thalassemia major with β 0 /β E genotype remain transfusion-independent for 23.4 and 20.1 months, respectively Patient with severe sickle cell disease (SCD ) in HGB-205 study remains free of transfusions and complications from SCD for nine months and is producing 49 percent
12/05/15
Summary Togglebluebird bio Reports New Beta-thalassemia Major Data from Northstar Study of LentiGlobin® at ASH Annual Meeting Transfusion independence observed in patients with non-β 0 /β 0 genotypes Transfusion reduction between 33 percent and 100 percent observed in patients with β 0 /β 0 genotype Company to webcast investor event, Sunday, Dec. 6 at 8:30 p.m. ET ORLANDO, Fla. --(BUSINESS WIRE)--Dec.
12/03/15
Summary Togglebluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy CAMBRIDGE, Mass. & SEOUL, Korea --(BUSINESS WIRE)--Dec. 3, 2015-- bluebird bio, Inc. (Nasdaq: BLUE) and ViroMed Co., Ltd. today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using
11/25/15
Summary Togglebluebird bio Announces Participation in 27th Annual Piper Jaffray Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 25, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today announced that members of the management team will
11/05/15
Summary Togglebluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of Hematology     – Six abstracts accepted for presentation – – Interim data on LentiGlobin in beta-thalassemia show six of six evaluable non-β 0 /β 0 patients are transfusion-independent as of July 31 st data cut-off; β 0 /β 0 patients have achieved varying degrees of transfusion reduction as of data cut-off –
11/04/15
Summary Togglebluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress -- Six abstracts accepted for presentation at American Society of Hematology (ASH) Annual Meeting -- -- Increased enrollment target for HGB-206 study of LentiGlobin ® in severe sickle cell disease (SCD) from eight patients to 20 patients –- -- Published a paper on megaTAL genome editing platform in
11/04/15
Summary Togglebluebird bio Announces Participation in 24th Annual Credit Suisse Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2015-- bluebird bio, Inc.  (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today announced that members of the management team will
10/19/15
Summary Togglebluebird bio Announces Presentation at Cooley’s Anemia Foundation Symposium Professor Marina Cavazzana presents overview on experience with investigational gene therapy in beta-thalassemia CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 19, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) announced that Marina Cavazzana, M.D., Ph.D., professor of hematology and director of the
09/24/15
Summary Togglebluebird bio Announces Participation in Leerink Partners Immuno-Oncology Roundtable CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 24, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced that members of the management team will participate in the Leerink Partners Immuno-Oncology Roundtable on Thursday, October 1, 2015 , with a fireside chat at 1:30 p.m. ET .
09/11/15
Summary Togglebluebird bio Announces Participation at Morgan Stanley Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 11, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced that members of the management team will participate in the Morgan Stanley Global Healthcare Conference on Friday, September 18, 2015 , with a presentation at 8:45 a.m. ET .
08/06/15
Summary Togglebluebird bio Reports Second Quarter 2015 Financial Results and Recent Operational Progress -- Presented promising new beta-thalassemia major and severe sickle cell disease data from HGB-205 study at EHA annual meeting -- -- Announced global regulatory strategy for LentiGlobin BB305 in beta-thalassemia major, with plans to pursue conditional and accelerated registration strategies in the
08/05/15
Summary Togglebluebird bio Announces Participation at the 2015 Wedbush PacGrow Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2015-- bluebird bio, Inc.  (Nasdaq:BLUE) today announced that members of the management team will participate in the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 , with a presentation at 9:10 a.m. ET .
06/23/15
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2015-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced the pricing of an underwritten
06/23/15
Summary Togglebluebird bio Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2015-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced that it has commenced an
06/22/15
Summary ToggleKite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers Collaboration Combines bluebird bio’s Gene Editing and Lentiviral Gene Delivery Technologies and Kite’s TCR Capabilities and Exclusive Rights to a TCR Directed Against the HPV-16 E6 Oncoprotein Exclusive Worldwide Co-Development and Co-Commercialization Collaboration SANTA MONICA, Calif., and
06/15/15
Summary TogglePhilip Gregory, D. Phil., Joins bluebird bio as Chief Scientific Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2015-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced that Philip Gregory , D.
06/13/15
Summary Togglebluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA Patient with Severe Sickle Cell Disease Producing 45% Anti-sickling Hemoglobin at Six Months and Has Been Free of Transfusions for More Than Three Months Patients with Beta-thalassemia Major Remain Transfusion-Independent at 16 and 14 Months, Respectively First Patient with Severe Sickle Cell
06/09/15
Summary Togglebluebird bio Completes NIH RAC Review of HGB-208 Pediatric Study Protocol CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 9, 2015-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, announced today the completion of the National
06/03/15
Summary ToggleCelgene and bluebird bio to Develop Anti-BCMA Product Candidates; bluebird bio Regains Rights to CAR T Programs Outside of BCMA Celgene to Pay bluebird bio $25 Million in New Research Funding bluebird bio to Independently Invest in and Pursue a Broad T cell-Based Immuno-oncology Strategy Investor Conference Call Scheduled for Wednesday, June 3, 2015 at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.
05/26/15
Summary Togglebluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)—May 26, 2015 -- bluebird bio, Inc. (Nasdaq: BLUE) and Five Prime Therapeutics, Inc. (Nasdaq: FPRX) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen
05/22/15
Summary Togglebluebird bio Announces Participation at the Jefferies 2015 Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced that members of the management team will participate in the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015 at 10:00 a.m. ET . The conference is being held June 1-4, 2015 in New
05/21/15
Summary Togglebluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association Presenting new and updated data from HGB-205 study in beta-thalassemia major and severe sickle cell disease, including first patient with sickle cell disease ever treated with gene therapy Company to host investor call on Monday, June 15, 2015 at 8:00 a.m. ET CAMBRIDGE, Mass.
05/19/15
Summary Togglebluebird bio Announces Global Regulatory Strategy for LentiGlobin BB305 in Beta-Thalassemia Major Company Plans to Pursue Conditional and Accelerated Registration Strategies in E.U. and U.S., Respectively Plans to Pursue Conditional Approval in E.U. Based on Data from Ongoing Northstar and HGB-205 Studies through Adaptive Pathways Pilot Program NIH RAC Will Review HGB-208 Pediatric Study
05/06/15
Summary Togglebluebird bio Reports First Quarter 2015 Financial Results and Business Updates -- Achievement of initial enrollment targets in Starbeam and Northstar studies -- -- Presenting HGB-205 beta-thalassemia/sickle cell disease study update at EHA -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2015-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing
04/30/15
Summary Togglebluebird bio Announces Participation at Two Upcoming Health Care Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced that members of the management team will participate in the following upcoming health care conferences: Deutsche Bank 40 th Annual Health Care Conference on Thursday, May 7, 2015 from 8:40 to 9:15
03/18/15
Summary Togglebluebird bio to Present at Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 18, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced that members of the management team will present at the Alliance for Regenerative Medicine’s 3 rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 4:20 p.m.
02/25/15
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Operational Progress CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2015-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today reported business highlights and financial
02/24/15
Summary Togglebluebird bio Announces Participation in Upcoming Investor Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 35 th Annual Cowen and Company Health Care Conference on Tuesday, March 3, 2015 at 11:20 a.m.
02/05/15
Summary Togglebluebird bio to Present at the Leerink Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2015-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced that management will present at the Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 8:05 a.m. EST . The conference is being held February 11-12, 2015 at the Waldorf Astoria
02/02/15
Summary ToggleFDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2015-- bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted
01/29/15
Summary Togglebluebird bio Announces Transition of Chief Scientific Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 29, 2015-- bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, today announced that Mitchell H. Finer , Ph.D., chief scientific officer (CSO), has
01/06/15
Summary Togglebluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2015-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that management will present at the 33 rd annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 2:30 p.m. PST . The conference is being held January 12-15, 2015 at the Westin
12/15/14
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 15, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the pricing of an underwritten public offering of 2,650,000
12/15/14
Summary Togglebluebird bio Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 15, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that it has commenced an underwritten public offering of $150
12/08/14
Summary Togglebluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free Data Presented at ASH; Company to Host Investor Call on December 10 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 8, 2014-- bluebird bio, Inc.  (Nasdaq: BLUE) today announced data from eight subjects treated with LentiGlobin BB305 drug product. In the first four subjects, each of whom had at least
11/12/14
Summary Togglebluebird bio Reports Fiscal Third Quarter 2014 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 12, 2014-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended
11/10/14
Summary ToggleJames M. DeTore joins bluebird bio as Chief Financial Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 10, 2014-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that James M. DeTore is joining the company as its Chief Financial
11/07/14
Summary Togglebluebird bio to Present at Three Upcoming Health Care Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Credit Suisse First Boston Bank Health Care Conference on Thursday, November 13, 2014 at 8:00 AM (MST) at the Biltmore Hotel , Phoenix, Arizona .
11/06/14
Summary Togglebluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference -- Two abstracts accepted for presentation -- Data to be presented from the Northstar Study and from the HGB-205 Study -- Company to host investor call on Wednesday, December 10, 2014 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2014-- bluebird bio, Inc.
10/14/14
Summary Togglebluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 14, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with severe sickle cell disease has
09/02/14
Summary Togglebluebird bio to Present at Morgan Stanley Global Health Care Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 2.30 PM ( EDT) at the Grand Hyatt New York Hotel , New York, NY .
08/12/14
Summary Togglebluebird bio Reports Fiscal Second Quarter 2014 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 12, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended
08/05/14
Summary Togglebluebird bio to Present at Two Upcoming Health Care Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Life Science Conference on Wednesday, August 13, 2014 at 12.40 PM (EDT) at the Parker Meridian Hotel , New York, NY .
07/16/14
Summary Togglebluebird bio Appoints Mark Vachon to its Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 16, 2014-- bluebird bio (Nasdaq: BLUE), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Mark Vachon has joined the company’s board of
07/08/14
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the pricing of an underwritten public offering of 3,000,000 shares
07/07/14
Summary Togglebluebird bio Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 7, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that it has commenced an underwritten public offering of $100
06/30/14
Summary Togglebluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company Acquisition brings Homing Endonuclease and MegaTAL gene-editing and novel cell signaling technologies with a broad range of potential therapeutic applications in gene therapy and cancer immunotherapies CAMBRIDGE, Mass. & SEATTLE --(BUSINESS WIRE)--Jun. 30, 2014-- bluebird bio, Inc.
06/14/14
Summary Togglebluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate First two patients in the HGB-205 Study achieved transfusion independence within two weeks of an autologous transplant with bluebird’s lentiviral gene therapy CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 14, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing
06/09/14
Summary Togglebluebird bio to Host a Conference Call to Discuss Initial Results from the HGB-205 Study in Beta-Thalassemia Major Subjects Conference call at 8:00am EDT on Monday, June 16, 2014 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 9, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced it was
05/21/14
Summary Togglebluebird bio to present initial clinical data from its HGB-205 Study in beta-thalassemia major patients at the 19th European Hematology Association Congress CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that bluebird bio and its clinical investigator plan to provide an
05/13/14
Summary Togglebluebird bio Reports Fiscal First Quarter 2014 Financial Results -- Initial clinical data from HGB-205 Study in beta-thalassemia major patients to be presented at the 19 th European Hematology Association Congress in June -- IND active for HGB-206 Study of LentiGlobin product candidate for the treatment of sickle cell disease CAMBRIDGE, Mass.
05/01/14
Summary Togglebluebird bio to Present at Three Upcoming Health Care Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Deutsche Bank 39 th Annual Health Care Conference on Thursday, May 8, 2014 at 8:00 AM( EDT ) at the InterContinental Boston Hotel , Boston, Massachusetts .
03/27/14
Summary Togglebluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia CAMBRIDGE, MA, March 27, 2014 – bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2
03/05/14
Summary Togglebluebird bio Reports Fiscal Year End 2013 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2014-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year
02/26/14
Summary Togglebluebird bio to Present at the Cowen and Company Health Care Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Cowen and Company 34 th Annual Health Care Conference to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel , Boston, MA.
02/05/14
Summary Togglebluebird bio to Present at the Leerink Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Leerink Global Healthcare Conference to be held February 12 - 13, 2014 at the Waldorf Astoria Hotel , New York, NY . Nick Leschly , Chief bluebird, will provide an
01/09/14
Summary Togglebluebird bio Appoints Dr James Mandell to its Board of Directors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2014-- bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell , M.D. has joined the company’s board of directors.
01/08/14
Summary Togglebluebird bio to Present at the J.P.Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2014-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the 32 nd Annual J.P. Morgan Healthcare Conference to be held January 13 - 16, 2014 at the Westin St Francis Hotel , San Francisco, CA.
12/26/13
Summary Togglebluebird bio Joins the NASDAQ Biotechnology Index CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 26, 2013-- bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the company was recently added to the NASDAQ Biotechnology
12/02/13
Summary Togglebluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 2, 2013-- bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled
11/27/13
Summary Togglebluebird bio to Present at Deutsche Bank BioFEST Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 27, 2013-- bluebird bio, Inc. (Nasdaq:BLUE) announces that management will present at the Deutsche Bank BioFEST Conference to be held December 2 - 3, 2013 at the Four Seasons Hotel , Boston, MA. Nick Leschly , Chief bluebird, will provide an overview of the
11/14/13
Summary Togglebluebird bio Reports Fiscal Third Quarter 2013 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2013-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended
10/28/13
Summary Togglebluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 28, 2013-- bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject in its phase 2/3 childhood cerebral
10/01/13
Summary Togglebluebird bio Joins the Russell 2000® Index CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2013-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the company has been added to the Russell 2000 ® , Russell
10/01/13
Summary ToggleRichard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy Established Thought Leader in the CAR-T Field CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2013-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that Dr.
09/04/13
Summary Togglebluebird bio to Present at Morgan Stanley Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2013-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Healthcare Conference to be held September 9 - 11, 2013 at the Grand Hyatt Hotel , New York, NY . Nick Leschly , Chief bluebird, will provide an overview
08/27/13
Summary Togglebluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 27, 2013-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has been named a 2014 Technology Pioneer , a prestigious award from the World Economic Forum honoring the world’s most innovative technology start-ups.
08/14/13
Summary Togglebluebird bio Reports Fiscal Second Quarter 2013 Financial Results CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 14, 2013-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended
08/06/13
Summary Togglebluebird bio to Present at Two Upcoming Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2013-- bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Securities Life Sciences Conference to be held August 13 - 14, 2013 at the Le Parker Meridien Hotel , New York, NY , and at the Canaccord Genuity Healthcare
06/24/13
Summary Togglebluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 24, 2013-- bluebird bio, Inc., a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced the closing of its initial public offering of 6,832,352 shares of
06/18/13
Summary Togglebluebird bio Announces Pricing of Initial Public Offering CAMBRIDGE, Mass.--( BUSINESS WIRE )--bluebird bio, Inc., a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced the pricing of its initial public offering of 5,941,176 shares of common stock at
05/06/13
Summary Togglebluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D. FOR IMMEDIATE RELEASE Investor Relations Richard E. T. Smith, Ph.D. bluebird bio, Inc (919) 588-3321 Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.
03/21/13
Summary Togglebluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology FOR IMMEDIATE RELEASE bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology - Separately, Celgene and bluebird bio to collaborate with the Center for Cell and Gene Therapy to advance new and existing CAR T-cell programs - CAMBRIDGE, Mass.
01/03/13
Summary Togglebluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference FOR IMMEDIATE RELEASE bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., January 3, 2013 – bluebird bio , a leader in the development of potentially transformative one-time gene therapies for severe genetic diseases, announced today that Nick Leschly,
09/07/12
Summary Togglebluebird bio to Present at the Rodman & Renshaw Annual Global Investment Conference FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio to Present at the Rodman & Renshaw Annual Global Investment Conference CAMBRIDGE, Mass., September 7, 2012 – bluebird bio , a leader in the development of innovative gene therapies for severe
07/25/12
Summary Togglebluebird bio Secures $60 Million in Oversubscribed Financing FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio Secures $60 Million in Oversubscribed Financing - Proceeds will Further Strengthen bluebird’s Proprietary Gene Therapy Platform and Advance Multiple Clinical Programs in Severe Genetic Disorders,
06/22/12
Summary ToggleBIO Welcomes bluebird bio CEO Nick Leschly to the Health Section Governing Board BIO Welcomes New Executive Committee and Section Governing Board Members 2012 BIO International Convention WASHINGTON -- The Board of Directors of the Biotechnology Industry Organization (BIO) elected its Executive Committee and added new members to Section Governing Boards in a meeting held in
06/19/12
Summary Togglebluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy CAMBRIDGE, Mass., June 19, 2012 -- bluebird bio, a leader in the development of innovative
05/31/12
Summary ToggleJohn Maraganore, Ph.D., Joins the bluebird bio Board of Directors FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 John Maraganore, Ph.D., Joins the bluebird bio Board of Directors CAMBRIDGE, Mass., May 31, 2012 – bluebird bio , a world leader in the development of innovative gene therapies for severe genetic disorders,
02/28/12
Summary Togglebluebird bio to Present at the Cowen and Company 32nd Annual Healthcare Conference FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio to Present at Cowen and Company 32nd Annual Health Care Conference CAMBRIDGE, Mass., February 28, 2012 – bluebird bio , a leader in the development of innovative gene therapies for severe genetic
02/16/12
Summary Togglebluebird bio Appoints David Davidson, M.D., as Chief Medical Officer FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer CAMBRIDGE, Mass., February 16, 2012 – bluebird bio , a world leader in the development of innovative gene therapies for severe genetic
02/09/12
Summary Togglebluebird bio to Present at the Leerink Swann 2012 Global Healthcare Conference FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio to Present at the Leerink Swann 2012 Global Healthcare Conference CAMBRIDGE, Mass., February 9, 2012 – bluebird bio , a leader in the development of innovative gene therapies for severe genetic
05/16/11
Summary Togglebluebird bio Adds Biotech Industry Veterans to Management Team and Board FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio Adds Biotech Industry Veterans to Management Team and Board bluebird bio Appoints Jeffrey T. Walsh as Chief Operating Officer and Daniel S. Lynch to Company’s Board of Directors CAMBRIDGE, Mass.,
04/20/11
Summary Togglebluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team FOR IMMEDIATE RELEASE Media Contact: Sheryl Seapy Pure Communications Inc. (949) 608-0841 bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team New Financing Will Further Advance the Beta-Thalassemia, Sickle Cell Anemia and ALD Clinical Programs While
03/21/11
Summary Togglebluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board FOR IMMEDIATE RELEASE Media Contact: Sheryl Seapy Pure Communications Inc. (949) 608-0841 bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board CAMBRIDGE, Mass., March 21, 2011 – bluebird bio , an emerging leader in the development of innovative gene therapies for
03/16/11
Summary Togglebluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia FOR IMMEDIATE RELEASE Media Contact: Sheryl Seapy Pure Communications Inc. (949) 608-0841 bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia CAMBRIDGE, Mass., March 16, 2011 –
01/03/11
Summary ToggleMassachusetts Life Sciences Center Announces 2010 Tax Incentives Targeted at Massachusetts Life Sciences Center Announces 2010 Tax Incentives Targeted at Cambridge-based Companies Center approves $23.9 million to foster job growth and stimulate the life sciences sectors, including $9.6 million for companies in Cambridge For Immediate Release.:
12/14/10
Summary Togglebluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy Cambridge, Mass. and Evry, France, December 14, 2010 – bluebird bio (formerly Genetix
11/02/10
Summary Togglebluebird bio Awarded Two Qualifying Therapeutic Discovery Project Program Grants FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 bluebird bio Awarded Two Qualifying Therapeutic Discovery Project Program Grants Grants Supported by the Patient Protection and Affordable Care Act of 2010 Cambridge, Mass., November 2, 2010 – bluebird bio
09/15/10
Summary ToggleNATURE Publishes Promising Results on Treatment of First Patient in bluebird bio's Phase 1/2 Beta-Thalassemia Study Media Contact: Dan Budwick Pure Communications, Inc. 973-271-6085 NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio’s Phase 1/2 Beta-Thalassemia Study Successful Clinical Response Achieved in beta-Thalassemia Patient with Single Treatment of Lentiviral Gene Therapy
09/09/10
Summary ToggleGenetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer FOR IMMEDIATE RELEASE Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer Cambridge, Mass. – September 9, 2010 – bluebird bio, an emerging leader in the development of
05/20/10
Summary ToggleNew Data From Adrenoleukodystrophy (ALD) Pilot Study Presented at American Society of Gene and Cell Therapy Show Three-Year Disease Stabilization of Patients Media Contact: Ashlea Kosikowski Pure Communications, Inc. 910-547-7093 FOR IMMEDIATE RELEASE: NEW DATA FROM ADRENOLEUKODYSTROPHY (ALD) PILOT STUDY PRESENTED AT AMERICAN SOCIETY OF GENE AND CELL THERAPY SHOW THREE-YEAR DISEASE STABILIZATION OF PATIENTS Cambridge, Mass. and Washington, D.C.
03/12/10
Summary Togglebluebird bio Appoints Mitchell Finer, Ph.D. as Chief Scientific Officer
03/12/10
Summary Togglebluebird bio Secures $35M in Series B Funding FOR IMMEDIATE RELEASE GENETIX PHARMACEUTICALS SECURES $35M IN SERIES B FUNDING Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy Cambridge, MA – March 12, 2010 – Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic
01/12/10
Summary Togglebluebird bio Adrenoleukodystrophy (ALD) Product Recognized in Science Magazine's Scientific Breakthroughs in 2009 FOR IMMEDIATE RELEASE: GENETIX PHARMACEUTICALS’ ADRENOLEUKODYSTROPHY (ALD) PRODUCT RECOGNIZED AS ONE OF SCIENCE MAGAZINE’S TOP 10 SCIENTIFIC BREAKTHROUGHS OF 2009 ALD Patients Featured in Science Article Now Living Healthy and Normal Lives Due to Groundbreaking Gene Therapy Cambridge, MA – January
11/06/09
Summary Togglebluebird bio Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD) FOR IMMEDIATE RELEASE: GENETIX PHARMACEUTICALS ANNOUNCES GLOBAL CLINICAL PLANS TO TREAT ADRENOLEUKODYSTROPHY (ALD) Gene Therapy Technology Licensed from National Institute of Health and Medical Research (INSERM) Featured in November Issue of Science Cambrige, MA – November 6, 2009 – Genetix

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contact

Stephanie Fagan

Senior Vice President, Corporate Communications

(201) 572-9581

sfagan@bluebirdbio.com

 

Investor Contact

Elizabeth Pingpank

Associate Director, Corporate Communications

(617) 914-8736

EPingpank@bluebirdbio.com